$1.24
+0.04 (+3.33%)
Open$1.19
Previous Close$1.20
Day High$1.30
Day Low$1.19
52W High$2.73
52W Low$0.88
Volume—
Avg Volume48.4K
Market Cap11.73M
P/E Ratio—
EPS$-2.05
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+3,172.6% upside
Current
$1.24
$1.24
Target
$40.58
$40.58
$25.27
$40.58 avg
$56.74
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.34M | 7.69M | 6.20M |
| Net Income | 836.8K | 704.4K | 655.3K |
| Profit Margin | 11.4% | 9.2% | 10.6% |
| EBITDA | 1.33M | 1.40M | 1.15M |
| Free Cash Flow | 524.0K | 541.1K | 340.9K |
| Rev Growth | +8.2% | -3.9% | -5.2% |
| Debt/Equity | 0.19 | 0.19 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |